Navigation Links
Researchers report progress using iPS cells to reverse blindness
Date:6/15/2011

INDIANAPOLIS Researchers have used cutting-edge stem cell technology to correct a genetic defect present in a rare blinding disorder, another step on a promising path that may one day lead to therapies to reverse blindness caused by common retinal diseases such as macular degeneration and retinitis pigmentosa which affect millions of individuals.

In a study appearing in an advance online publication of the journal Stem Cells on June 15, 2011, investigators used recently developed technology to generate induced pluripotent stem (iPS) cells from a human patient with an uncommon inherited eye disease known as gyrate atrophy. This disorder affects retinal pigment epithelium (RPE) cells, the cells critical to the support of the retina's photoreceptor cells, which function in the transmission of messages from the retina to parts of the brain that interpret images.

"When we generate iPS cells, correct the gene defect that is responsible for this disease, and guide these stem cells to become RPE cells, these RPE cells functioned normally. This is exciting because it demonstrates we can fix something that is out of order. It also supports our belief that in the future, one might be able to use this approach for replacement of cells lost or malfunctioning due to other more common diseases of the retina," said lead study author cell biologist Jason Meyer, Ph.D., assistant professor of biology in the School of Science at Indiana University-Purdue University Indianapolis.

Macular degeneration is the most common cause of blindness, affecting an estimated 25-30 million people worldwide. One and a half million people worldwide are affected by retinitis pigmentosa.

Because iPS cells can be derived from the specific patient who needs them, use of these cells may avoid the problem of transplant rejection. In the study, vitamin B-6 also was used to treat the damaged RPE cells producing healthy cells that functioned normally. The retina is a relatively easily accessible part of the central nervous system, which makes it an attractive target for correction with iPS cells. Researchers are hopeful that once the gene defect responsible for a blinding disorder is corrected in iPS cells, these cells may be able to restore vision.


'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-274-7722
Indiana University-Purdue University Indianapolis School of Science
Source:Eurekalert  

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers report progress using iPS cells to reverse blindness
(Date:1/18/2017)... NC (PRWEB) , ... January 18, 2017 , ... The ... remain on Team V, its official endurance training and fundraising team, to compete in ... V Foundation welcomes those inspired to finish the world’s oldest annual marathon to join ...
(Date:1/18/2017)... ... January 18, 2017 , ... Park Agencies ... planning services to families and business owners in the greater Kansas City area, ... with developmental disabilities. , The Lakemary Center is a comprehensive educational resource center ...
(Date:1/18/2017)... ... 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), a ... Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. The ... thought leader interaction in, live video and interactive digital platforms. , In making ...
(Date:1/18/2017)... ... , ... Floundering on New Year’s resolutions? Need an excuse to get back ... The U.S. Apple Association agrees and recommends starting each day with apples, a ... heart disease. , The U.S. Apple Association – which represents apple growers and producers ...
(Date:1/17/2017)... California (PRWEB) , ... January 17, 2017 , ... ... have a point of difference. Eden Activewear is a stand-out company for several ... are exclusively online and only manufacture on demand, this is called 'Agile' manufacturing ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017 Research and Markets has ... 2017 - 2024" report to their offering. ... This new report revisits the ... that was issued in May of 2015. Self-healing is an area ... previous analysis we projected a market potential of $2.7 billion ($US) ...
(Date:1/17/2017)... -- Paragon Bioservices received a multiple-award, indefinite-delivery, indefinite-quantity ... a variety of National Institute of Allergy ... activities. The IDIQ mechanism will allow Paragon to ... awards up to $159 million. Paragon ... development of biopharmaceuticals, is one of four awardees ...
(Date:1/17/2017)... Management to Discuss Acquisition of ... KIT-302 Development On Track For An NDA ... Q1 2017   ... Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an innovative biopharmaceutical company, ... rd at 8:30am Eastern Time to discuss the recent acquisition of a ...
Breaking Medicine Technology: